Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 19, 2026

Arcadis Q4 and Full Year 2025 Results: Mixed results, repositioning for next growth phase

View original at finance.yahoo.com
Arcadis Q4 and Full Year 2025 Results: Mixed results, repositioning for next growth phase Arcadis N.V…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Operating EBITA margin target for 2026 of 11.7%-12.0% will be supported by overhead reductions (driving 30 bps savings), further rightsizing, GEC contribution and disciplined project selection

    80% confidence
  • Mobility performance is expected to remain mixed, with good pipeline opportunities although the timing of large contract awards in the pipeline is uncertain

    80% confidence
  • 2026 will be a year of transition, and while the outlook for Resilience is robust, the Places outlook remains uncertain

    80% confidence
  • Heather Polinsky with her strong track record, including leading the Resilience business since 2021, is the right person to lead Arcadis to its next phase

    80% confidence
  • Priorities for 2026 and beyond are clear: focus where we can win and grow, simplify to accelerate, and drive cultural change. Will become a more client-centric organization, drive efficiencies and increase cross-selling opportunities.

    80% confidence
  • Embedding a high-performance culture by clarifying accountability and aligning incentivization directly to results

    80% confidence
  • 2025 was a challenging year for Arcadis, with mixed results. While strong performance was reported in high-growth markets including Water Optimization, Energy Transition and Climate Adaptation, headwinds in Property & Investment, Environmental Restoration and large mobility projects weighed on overall performance.

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com